Gufic BioSciences Q3 Results
- BSE: 509079
- NSE: GUFICBIO
- ISIN: INE742B01025
- Sector: Biotechnology & Drugs
BSE
290.50
-10.80 (-3.58%)
-10.80 (-3.58%)Volume1.06 K
Updated: Mon 20 Apr, 2026 | 15:29:49
NSE
293.30-6.45 (-2.15%)
-6.45 (-2.15%)Volume31.43 K
Updated: Mon 20 Apr, 2026 | 15:40:47
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Incomeâ‚ą231.41 Cr.(11.37%)
- Operating Profitâ‚ą25.29 Cr.(-13.72%)
- Profit After Taxâ‚ą12.42 Cr.(-35.65%)
- Operating Margin10.93%(-22.52%)
Note: Comparison is on YoY basis
Quarterly - Gufic BioSciences Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 206.12 | 169.86 | -0.41% | 169.46 | 15.48% |
| Depreciation/ Amortization | 7.69 | 4.30 | -1.04% | 4.14 | 66.56% |
| Operating Income | 25.29 | 34.32 | -15.92% | 32.31 | -13.72% |
| Net Income | 12.42 | 21.77 | -26.16% | 22.26 | -35.65% |
| Other Operating Expenses Total | 57.32 | 40.96 | 0.00% | 39.38 | 25.30% |
| Net Income Before Taxes | 17.72 | 29.25 | -21.61% | 29.56 | -32.52% |
| Total Revenue | 231.41 | 204.18 | -2.38% | 201.78 | 11.37% |
| Selling/ General/ Admin Expenses Total | 40.09 | 28.47 | 7.04% | 30.60 | 18.05% |
| Diluted Normalized EPS | 1.24 | 2.17 | -26.19% | 2.23 | -35.75% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
âś•
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.